Abstract
Objective
The novel estrogen receptor-α (ER-α) variant ER-α36 is reported to be functional in the estrogen signaling pathway and is related to tamoxifen resistance in breast cancer. However, ER-α36 tends to be a favorable factor for survival in patients without tamoxifen therapy. To investigate the mechanisms behind this paradox, we determined the differences between the transcriptional profiles of ER-α36 and full-length ER-α (ER-α66) in breast cancers and matched normal tissues.
Methods
We analyzed ER-α36 and ER-α66 messenger RNA (mRNA) levels in 74 pairs of breast cancers and matched normal tissues using a real-time quantitative polymerase chain reaction (PCR) assay, and correlated the results with their clinicopathological characteristics.
Results
Breast cancers expressed lower ER-α36 mRNA levels than matched normal tissues regardless of their ER-α66 expression status. Down-regulation of ER-α36 mRNA was correlated with local progression, lymph node metastasis, and advanced cancer stage. The level of ER-α66 mRNA was lower in ER-α negative breast cancers compared with matched normal tissues. No differences in ER-α66 mRNA levels were observed during cancer progression.
Conclusion
Down-regulation of ER-ga36 is associated with carcinogenesis and progression of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anandappa, S.Y., Sibson, R., Platt-Higgins, A., Winstanley, J.H., Rudland, P.S., Barraclough, R., 2000. Variant estrogen receptor alpha mRNAs in human breast cancer specimens. Int. J. Cancer, 88(2):209–216. [doi:10.1002/1097-0215(20001015)88:2〈209::AID-IJC10〉3.0.CO;2-M]
Dunnwald, L.K., Rossing, M.A., Li, C.I., 2007. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res., 9(1):R6. [doi:10.1186/bcr1639]
Erenburg, I., Schachter, B., Mira y Lopez, R., Ossowski, L., 1997. Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its re-expression: interference with estrogen-stimulated properties of malignant transformation. Mol. Endocrinol., 11(13):2004–2015. [doi:10.1210/me.11.13.2004]
Fisher, B., Redmond, C., Fisher, E.R., Caplan, R., 1988. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol., 6(7): 1076–1087.
Flouriot, G., Brand, H., Denger, S., Metivier, R., Kos, M., Reid, G., Sonntag-Buck, V., Gannon, F., 2000. Identification of a new isoform of the human estrogen receptor-alpha (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J., 1919 (17):4688–4700 [doi:10.1093/emboj/19.17.4688]
Fuqua, S.A., Fitzgerald, S.D., Allred, D.C., Elledge, R.M., Nawaz, Z., McDonnell, D.P., O’Malley, B.W., Greene, G.L., McGuire, W.L., 1992. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res., 52(2):483–486.
Garcia Pedrero, J.M., Zuazua, P., Martinez-Campa, C., Lazo, P.S., Ramos, S., 2003. The naturally occurring variant of estrogen receptor (ER) ERDeltaE7 suppresses estrogen-dependent transcriptional activation by both wildtype ERalpha and ERbeta. Endocrinology, 144(7):2967–2976. [doi:10.1210/en.2002-0027]
Goldhirsch, A., Glick, J.H., Gelber, R.D., Coates, A.S., Thurlimann, B., Senn, H.J., 2005. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol., 16(10):1569–1583. [doi:10.1093/annonc/mdi326]
Gotteland, M., Desauty, G., Delarue, J.C., Liu, L., May, E., 1995. Human estrogen receptor mRNA variants in both normal and tumor tissues. Mol. Cell. Endocrinol., 112(1): 1–13. [doi:10.1016/0303-7207(95)03576-S]
Hsiao, W.C., Cho, W.C., Lin, P.W., Lin, S.L., Lee, W.Y., Young, K.C., 2006. Quantitative profile of estrogen receptor variants/isoforms in Taiwanese women with breast cancer. Eur. J. Surg. Oncol., 32(5):492–497. [doi:10.1016/j.ejso.2006.02.010]
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., 2009. Cancer statistics, 2009. CA Cancer J. Clin., 59(4): 225–249. [doi:10.3322/caac.20006]
Jiang, H., Teng, R., Wang, Q., Zhang, X., Wang, H., Wang, Z., Cao, J., Teng, L., 2008. Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J. Steroid Biochem. Mol. Biol., 112(1–3):20–24. [doi:10.1016/j.jsbmb.2008.07.004]
Koduri, S., Fuqua, S.A., Poola, I., 2000. Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J. Cancer Res. Clin. Oncol., 126(5):291–297. [doi:10.1007/s004320050345]
Kong, E.H., Pike, A.C., Hubbard, R.E., 2003. Structure and mechanism of the oestrogen receptor. Biochem. Soc. Trans., 31(Pt 1):56–59.
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.R., Chambon, P., 1987. Functional domains of the human estrogen receptor. Cell, 51(6):941–951. [doi:10.1016/0092-8674(87)90581-2]
Kumar, V.L., Kumar, S., Srivastava, A., Kumar, V., 2006. Observations on the presence of E domain variants of estrogen receptor-alpha in the breast tumors. J. Surg. Oncol., 94(4):332–337. [doi:10.1002/jso.20588]
Lee, L.M., Cao, J., Deng, H., Chen, P., Gatalica, Z., Wang, Z.Y., 2008. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res., 28(1B):479–483.
Leygue, E., Huang, A., Murphy, L.C., Watson, P.H., 1996. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res., 56(19):4324–4327.
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC t method. Methods, 25(4):402–408 [doi:10.1006/meth.2001.1262]
Pfeffer, U., Fecarotta, E., Vidali, G., 1995. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and MCF-7 cells. Cancer Res., 55(10):2158–2165.
Ponglikitmongkol, M., Green, S., Chambon, P., 1988. Genomic organization of the human oestrogen receptor gene. EMBO J., 7(11):3385–3388.
Poola, I., Speirs, V., 2001. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol., 78(5): 459–469. [doi:10.1016/S0960-0760(01)00118-2]
Poola, I., Koduri, S., Chatra, S., Clarke, R., 2000. Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using spliced targeted primer approach. J. Steroid Biochem Mol. Biol., 72(5):249–258. [doi:10.1016/S0960-0760(00)00033-9]
Poola, I., Clarke, R., DeWitty, R., Leffall, L.D., 2002. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women. Cancer, 94(3):615–623. [doi:10.1002/cncr.10274]
Shi, L., Dong, B., Li, Z., Lu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., et al., 2009. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol., 27(21):3423–3429. [doi:10.1200/JCO.2008.17.2254]
Ström, A., Hartman, J., Foster, J.S., Kietz, S., Wimalasena, J., Gustafsson, J.A., 2004. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA, 101(6):1566–1571. [doi:10.1073/pnas.0308319100]
Wang, Z., Zhang, X., Shen, P., Loggie, B.W., Chang, Y., Deuel, T.F., 2005. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun., 336(4):1023–1027. [doi:10.1016/j.bbrc.2005.08.226]
Wang, Z.Y., Zhang, X.T., Shen, P., Loggie, B.W., Chang, Y., Deuel, T.F., 2006. A variant of estrogen receptor-alpha, hER-alpha36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. USA, 103(24):9063–9068. [doi:10.1073/pnas.0603339103]
Author information
Authors and Affiliations
Corresponding authors
Additional information
The two authors contributed equally to this work
Project supported by the National Basic Research Program (973) of China (No. 2009CB521704), the National Natural Science Foundation of China (No. 30772510), the Ministry of Health of China (No. WKJ2006-2-008), the Department of Science and Technology of Zhejiang Province (No. 2007C24011), the Natural Science Foundation of Zhejiang Province (No. R206060), China
Rights and permissions
About this article
Cite this article
Zheng, Y., Zhang, J., Xu, Zz. et al. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues. J. Zhejiang Univ. Sci. B 11, 144–150 (2010). https://doi.org/10.1631/jzus.B0900266
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B0900266